NGAL AS BIOMARKER FOR MINERALOCORTICOID RECEPTOR ACTIVATION
摘要
The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
申请公布号
EP2344671(A1)
申请公布日期
2011.07.20
申请号
EP20090736992
申请日期
2009.10.21
申请人
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)